Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31095730 | 0.85 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AHTTHTR2A | |
| SCHEMBL26386366 | 0.75 | EPHX1 (0.48) | ALDH1A1MEN1KMT2AHTTRAB9A | |
| SCHEMBL10639422 | 0.75 | TPSAB1 (0.50) | ALDH1A1KMT2AGBA1HTTRAB9A | |
| Trifluoroacetic Acid SCHEMBL8095167 | 0.75 | SLC6A2 (0.41) | ALDH1A1HTR2ACCR5SIGMAR1SMN1; SMN2 | |
| SCHEMBL15618793 | 0.74 | ALDH1A1 (0.55) | ALDH1A1HTTHTR2ARAB9ASMN1; SMN2 | |
| SCHEMBL8095172 | 0.74 | CCR5 (0.42) | CCR5 | |
| SCHEMBL1058888 | 0.74 | SIGMAR1 (0.60) | ALDH1A1KMT2ARAB9ACCR5SIGMAR1 | |
| SCHEMBL991790 | 0.74 | ALDH1A1 (0.52) | ALDH1A1HTTHTR2ARAB9ASMN1; SMN2 | |
| SCHEMBL13543078 | 0.74 | CCR5 (0.46) | HTR2ACCR5 | |
| SCHEMBL13684200 | 0.73 | ALDH1A1 (0.54) | ALDH1A1HTTHTR2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084445-B2 | Broad-spectrum carbapenems | VenatoRx Pharmaceuticals, Inc. (US) | 2024-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084445-B2 | Broad-spectrum carbapenems | MGAM, ALPI, SI | ALDH1A1 3603/4885MEN1 3883/4885KMT2A 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.